Treating HER2-mutant advanced biliary tract cancer with neratinib: benefits of HER2-directed targeted therapy in the phase 2 SUMMIT ‘basket’ trial
Year: 2019
Type: article
Source: Annals of Oncology
Institutions: Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Vall d'Hebron Hospital Universitari, Hospital Universitario Fundación Jiménez Díaz, USC Norris Comprehensive Cancer Center, Mayo Clinic in Arizona, Peter MacCallum Cancer Centre, Copenhagen University Hospital, Rigshospitalet, Rabin Medical Center, Puma Biotechnology (United States), Pivotal (Spain), The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2958849371